Traumatic Brain Injury; Needs and Treatment Options in the Chronic Phase

March 11, 2022 updated by: Cecilie Røe, Oslo University Hospital

Traumatic Brain Injury; Needs and Treatment Options in the Chronic Phase. A Randomized Controlled Community-based Intervention

Traumatic brain injury (TBI) is a condition affecting the persons' central nervous system with a need for extensive and highly specialized initial health care provision followed by comprehensive rehabilitation efforts. Frequent and life-long medical, cognitive, emotional and behavioral changes are expected. The community-based services are largely responsible for dealing with the chronic challenges affecting people with TBI.

120 patients >16 years at the time of injury and between 18 and 72 years at inclusion, with clinical TBI diagnosis on acute admission and verified injury-related intracranial abnormalities reporting cognitive, emotional and physical problems more than 2 years after the injury will be included and randomized to a patient-centered in-home program intervention and treatment as usual. The intervention consists of an individualized and goal-oriented intervention will be provided in the persons' home environment, in close collaboration with family members and local health care providers when available. Assessments will be conducted at baseline, at the end of the intervention 4 months after inclusion and one year after inclusion. Primary outcome is participation (Part-O) and TBI specific health related quality of life (Qolibri). Secondary outcomes include goal attainment within individualized targeted outcome areas, depression and anxiety, symptom burden, unmet health care needs and acceptability of intervention as assessed by patient, family member and health professional. The project will contribute to increased understanding of knowledge transfer processes, and dissemination of evidence based practice for TBI. Thus, the project has the potential to improve the current health care for patients with TBI and its delivery.

Study Overview

Detailed Description

Traumatic brain injury (TBI) is a condition affecting the persons' central nervous system with a need for extensive and highly specialized initial health care provision followed by comprehensive rehabilitation efforts. Frequent and life-long medical, cognitive, emotional and behavioral changes are expected. The community-based services are largely responsible for dealing with the chronic challenges affecting people with TBI.

120 patients >16 years at the time of injury and between 18 and 72 years at inclusion, with clinical TBI diagnosis on acute admission and verified injury-related intracranial abnormalities reporting cognitive, emotional and physical problems more than 2 years after the injury will be included and randomized to a patient-centered in-home program intervention and treatment as usual. The intervention consists of individualized and goal-oriented strategies provided in the persons' home environment in close collaboration with family members and local health care providers. The original protocol describes a total of 8 sessions of which 2 will be telephone based. Due to the Corona pandemic hittting Norway in March 2020 the home visits had to be reduced and adapted to the individual situation of the participants. The protocol now includes 8 sessions with up to 6 of them being delivered by video. The intervention will be provided in addition to the usual treatment the participants receive in the municipality. The control group will receive the usual treatment provided in the municipality. Assessments will be conducted at baseline, at the end of the intervention 4-5 months after inclusion and one year after inclusion. Primary outcome is participation (Part-O) and TBI specific health related quality of life (Qolibri). Secondary outcomes include goal attainment within individualized targeted outcome areas, depression and anxiety, symptom burden, unmet health care needs and acceptability of intervention as assessed by patient, family member and health professional. In March 2020 a few additional questions regarding the impact of the Corona pandemic on health and participation has been included. The closedown periods of the Norwegian Society during Covid-19 will be used as covariate and/or predictors in the analysis. The project will contribute to increased understanding of knowledge transfer processes, and dissemination of evidence based practice for TBI. Thus, the project has the potential to improve the current health care for patients with TBI and its delivery.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oslo, Norway, 0407
        • OUH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 72 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients >16 years at injury and 18-72 years at inclusion, with clinical TBI diagnosis on acute admission and CT/MRI verified injury-related intracranial abnormalities.
  • Patients reporting TBI-related cognitive, emotional and physical problems and/or reduced physical and mental health and/or difficulties with participation in activities with family, friends and in the community at least 2 years after the injury,
  • Able to provide informed consent and collaborate in the goal setting processing.
  • Living at home at study inclusion.

Exclusion Criteria:

  • Patients are excluded if they have severe preexisting neurological disorder that would confound outcome assessments and severe psychiatric diseases
  • Patients unable to provide informed consent or participate in a goal-setting process.
  • Participants with insufficient fluency in Norwegian to allow for communication with therapists and outcome assessors will also be excluded.
  • Substance abuce or history of violence that could represent a security risk for the professionals delivering the intervention

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patient-centered in home rehabilitation
Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
Active Comparator: Control
Usual follow-up assessment and health care and rehabilitation services provided in the municipality
Usual follow-up in the municipality

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participation
Time Frame: 12 months
Participation assessment and Recombined Tools- Objective (PART-O) (Social domain)
12 months
General Health
Time Frame: 12 months
Quality of Life after Brain Injury (Qolibri overall scale, sum score of 6 items )
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global functioning
Time Frame: 4 and 12 months
Glasgow outcome scale extended (GOSE) (score 0-8)
4 and 12 months
Depression
Time Frame: 4 months (patients and family) and 12 months intervention (patients)
Patients Health Questionnaire (PHQ-9) (patients and family members)
4 months (patients and family) and 12 months intervention (patients)
Physical and mental health (EQ-5D) and quality-adjusted life years, (QALYs)
Time Frame: 4 and 12 months
Physical and mental health (scored according to the EQ-5D algoritm )and QALYs (patients) and overall health (on a scale 0-100,family members)
4 and 12 months
Acceptability and satisfaction with the intervention
Time Frame: 4 and 12 months
Acceptability Scale assessed by patients, care providers and family members (sum score)
4 and 12 months
Target outcome areas
Time Frame: 4 and 12 months
The patient nominate their three most important problems and the difficulties they have with them on a scale from 0 to 4. Changes in the difficulty score is evaluated.
4 and 12 months
Symptom burden
Time Frame: 4 and 12 months
Rivermead post-concussion questionnaire (RPQ)(patients) (scoring algoritm)
4 and 12 months
Patient and family members, evaluating self-awareness and functioning. Patient and family members, evaluating self-awareness and functioning
Time Frame: 4 and 12 months
Patient Competency Rating Scale (PCRS) (sum score) rated by patient and family member
4 and 12 months
Caregiver burden (Caregiver burden scale)
Time Frame: 4 and 12 months
Caregiver burden-family member
4 and 12 months
Anxiety Disorder Measurement (GAD-7)
Time Frame: 4 and 12 months
Generalised Anxiety Disorder Measurement (GAD-7) (sumscore 7 items, 0-21)
4 and 12 months
Participation
Time Frame: 4 months
Participation assessment and Recombined Tools- Objective (PART-O) (3 domains and total score
4 months
General Health
Time Frame: 4 months
Quality of Life after Brain Injury (Qolibri overall scale, sum score of 6 items )
4 months
Participation
Time Frame: 12 months
Participation assessment and Recombined Tools- Objective (PART-O) (domain Round and about and Productivity, Total score
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Cecilie Røe, OUH

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2018

Primary Completion (Actual)

April 30, 2021

Study Completion (Actual)

December 31, 2021

Study Registration Dates

First Submitted

May 9, 2018

First Submitted That Met QC Criteria

June 1, 2018

First Posted (Actual)

June 4, 2018

Study Record Updates

Last Update Posted (Actual)

March 28, 2022

Last Update Submitted That Met QC Criteria

March 11, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Only aggregated data will be shared according to the Norwegian legislation

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe